Multicancer Screening Market by Product, Test Type, Technology, Cancer Type, End User - Global Forecast 2025-2030- Product Image

Sale

Multicancer Screening Market by Product, Test Type, Technology, Cancer Type, End User - Global Forecast 2025-2030

Report
191 Pages
October 2024
Region: Global
360iResearch™
ID: 5925117

UP TO €681EUR$697USD£569GBP OFF until Dec 31^st 2024

The Multicancer Screening Market grew from USD 1.40 billion in 2023 to USD 1.53 billion in 2024. It is expected to continue growing at a CAGR of 9.90%, reaching USD 2.72 billion by 2030.

The multicancer screening market is advancing rapidly, driven by the need for early detection techniques that can identify multiple types of cancer from a single test, potentially improving survival rates and reducing healthcare costs. The necessity of multicancer screening hinges on the fact that many cancers are detected too late, making early diagnostic solutions crucial for proactive healthcare management. Applications of multicancer screening span hospitals, diagnostic laboratories, and specialized cancer treatment centers. It enables comprehensive cancer risk assessment and personalized treatment plans. End-use scope extends to primary care settings where preventive approaches and routine screenings are becoming integral.

Key growth factors include technological advancements in genomic and proteomic profiling, coupled with increasing investments in research and development from both private and public sectors. The rising incidence of cancer globally, along with the demand for non-invasive diagnostic procedures, further propels market expansion. However, limitations such as the high cost of tests, regulatory challenges, and the complexity of data interpretation present significant hurdles. Notably, issues regarding the accuracy and potential for overdiagnosis may also impede market acceptance.

Despite challenges, potential opportunities include the integration of artificial intelligence to enhance accuracy and efficiency, and the development of cost-effective multicancer screening tests accessible to diverse populations. Fostering partnerships between biotech firms and healthcare providers can facilitate the creation of innovative solutions and distribution networks. Advanced research into biomarker discovery and validation is poised to transform screening processes.

Innovation in digital health solutions, particularly in telemedicine and mobile health technologies, presents promising avenues for research and business growth, aiming to bring multicancer screening into more routine healthcare settings. The market is characterized by its dynamic nature, driven by continuous technological advancements, competitive pressures, and evolving regulatory landscapes, necessitating agile adaptation strategies.

Understanding Market Dynamics in the Multicancer Screening Market

The Multicancer Screening Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of cancer disease and rising aging population
- Several government initiatives promoting multicancer screening in healthcare facilities
Market Restraints
- Time-consuming procedures coupled with high cost associated with multicancer screening
Market Opportunities
- Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
- Rising R&D activities for the development of cancer diagnostics treatment procedures
Market Challenges
- Concerns associated with adequate safety and efficacy data and variability in test performance

Exploring Porter’s Five Forces for the Multicancer Screening Market

Porter’s Five Forces framework further strengthens the insights of the Multicancer Screening Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Multicancer Screening Market

External macro-environmental factors deeply influence the performance of the Multicancer Screening Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Multicancer Screening Market

The Multicancer Screening Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Multicancer Screening Market

The Multicancer Screening Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- AI and Machine Learning-Based Platforms
- Blood-Based Tests
- Breath Analysis Tests
- Fecal Tests
- Gene Panels/Test Panels
- Imaging Tests
  - Computed Tomography
  - Magnetic Resonance Imaging
  - Positron Emission Tomography
- Saliva & Buccal Swab Test
- Tissue Test
- Urine-Based Tests
Test Type
- In-vitro diagnostics
- Laboratory Developed Tests
Technology
- Fluorescence In-Situ Hybridization
- Immunohistochemistry
- Next-Generation Sequencing
- Polymerase Chain Reaction
Cancer Type
- Brain/Nervous System
- Breast & Gynecologic
- Endocrine
- Gastrointestinal
- Genitourinary
- Hematological Malignancies
- Lung
- Sarcoma
- Skin
End User
- Academic & Research Institutions
- Diagnostic & Clinical Laboratories
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer disease and rising aging population
5.1.1.2. Several government initiatives promoting multicancer screening in healthcare facilities
5.1.2. Restraints
5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
5.1.3. Opportunities
5.1.3.1. Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
5.1.4. Challenges
5.1.4.1. Concerns associated with adequate safety and efficacy data and variability in test performance
5.2. Market Segmentation Analysis
5.2.1. Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
5.2.2. Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
5.2.3. Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
5.2.4. Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
5.2.5. End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Multicancer Screening Market, by Product

6.1. Introduction
6.2. AI and Machine Learning-Based Platforms
6.3. Blood-Based Tests
6.4. Breath Analysis Tests
6.5. Fecal Tests
6.6. Gene Panels/Test Panels
6.7. Imaging Tests
6.7.1. Computed Tomography
6.7.2. Magnetic Resonance Imaging
6.7.3. Positron Emission Tomography
6.8. Saliva & Buccal Swab Test
6.9. Tissue Test
6.10. Urine-Based Tests

7. Multicancer Screening Market, by Test Type

7.1. Introduction
7.2. In-vitro diagnostics
7.3. Laboratory Developed Tests

8. Multicancer Screening Market, by Technology

8.1. Introduction
8.2. Fluorescence In-Situ Hybridization
8.3. Immunohistochemistry
8.4. Next-Generation Sequencing
8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Cancer Type

9.1. Introduction
9.2. Brain/Nervous System
9.3. Breast & Gynecologic
9.4. Endocrine
9.5. Gastrointestinal
9.6. Genitourinary
9.7. Hematological Malignancies
9.8. Lung
9.9. Sarcoma
9.10. Skin

10. Multicancer Screening Market, by End User

10.1. Introduction
10.2. Academic & Research Institutions
10.3. Diagnostic & Clinical Laboratories
10.4. Hospitals

11. Americas Multicancer Screening Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Multicancer Screening Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology
14.3.2. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
14.3.3. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
14.3.4. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
14.3.5. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
14.3.6. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
14.3.7. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
14.3.8. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
14.3.9. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.

List of Figures

FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 16. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 18. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 20. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 24. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
TABLE 43. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 44. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 45. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 46. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 50. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 51. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 52. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 53. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 54. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 55. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 56. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 57. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 58. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 59. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 60. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 61. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 62. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 63. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 64. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 65. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 66. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 67. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 68. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 69. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 70. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 71. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 72. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 73. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 74. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 75. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 76. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 77. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 78. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 79. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 80. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
TABLE 81. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 82. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 83. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 84. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 85. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 86. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 87. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 88. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 89. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 90. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 91. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 92. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 93. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 94. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 95. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 96. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 97. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 98. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 99. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 100. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 101. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 102. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 103. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 104. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 105. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 106. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 107. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 108. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 109. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 110. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 111. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 112. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 113. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 114. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 115. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 116. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 117. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 118. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 119. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 120. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 121. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 122. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 123. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 124. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 125. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 126. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 127. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 128. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 129. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 130. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 131. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 132. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 133. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 134. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 135. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 136. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 137. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 138. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 139. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 140. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 141. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 142. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 143. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 144. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 145. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 146. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 147. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 148. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 149. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 150. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 151. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 152. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 153. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 154. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 155. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 156. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 157. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 158. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 159. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
TABLE 167. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 168. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 169. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 170. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 171. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 172. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 173. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 174. EGYPT MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 175. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 176. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 177. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 178. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 179. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 180. FINLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 181. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 182. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 183. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 184. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 185. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 186. FRANCE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 187. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 188. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 189. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 190. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 191. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 192. GERMANY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 193. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 194. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 195. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 196. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 197. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 198. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 199. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 200. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 201. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 202. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 203. ITALY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 204. ITALY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 205. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 206. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 207. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 208. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 209. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 210. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 211. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 212. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 213. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 214. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 215. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 216. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 217. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 218. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 219. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 220. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 221. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 222. NORWAY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 223. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 224. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 225. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 226. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 227. POLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 228. POLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 229. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 230. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 231. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 232. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 233. QATAR MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 234. QATAR MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 235. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 236. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 237. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 238. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 239. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 240. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 241. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 242. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 243. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 244. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 245. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 246. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 247. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 248. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 249. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 250. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 251. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 252. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 253. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 254. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 255. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 256. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 257. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 258. SPAIN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 259. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 260. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 261. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 262. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 263. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 264. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 265. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 266. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 267. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 268. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 269. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 270. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 271. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 272. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 273. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 274. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 275. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 276. TURKEY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 277. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 278. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 279. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 280. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 281. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 282. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 283. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 284. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 285. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 286. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 287. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
TABLE 288. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
TABLE 289. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
TABLE 290. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
TABLE 291. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
TABLE 292. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
TABLE 293. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 294. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Multicancer Screening market, which are profiled in this report, include:

ANPAC Bio-Medical Science Co., Ltd.
Burning Rock Biotech Limited
Caris Life Sciences
Coyne Medical Ltd.
Delfi Diagnostics, Inc.
Elypta AB
EpiCypher, Inc.
Epigenomics AG
Exact Sciences Corporation
Foundation Medicine, Inc.
Freenome Holdings, Inc.
Fulgent Genetics, Inc.
Gene Solutions
Grail, LLC by Illumina, Inc.
Guangzhou AnchorDx Medical Co., Ltd.
Guardant Health, Inc.
Invitae Corporation
Laboratory Corporation of America Holdings
Lucence Health Inc.
Micronoma, Inc.
MiRXES Pte Ltd.
Myriad Genetics, Inc.
Natera, Inc.
Naveris, Inc.
NeoGenomics Laboratories
OneTest
Siemens Healthineers AG
StageZero Life Sciences. Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	191
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.53 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.72 Billion
Compound Annual Growth Rate	9.9%
Regions Covered	Global
No. of Companies Mentioned	29

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3466EUR$3,545USD£2,895GBP €3851EUR$3,939USD£3,217GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6132EUR$6,272USD£5,122GBP €6813EUR$6,969USD£5,691GBP

Understanding Market Dynamics in the Multicancer Screening Market

Exploring Porter’s Five Forces for the Multicancer Screening Market

Applying PESTLE Analysis to the Multicancer Screening Market

Analyzing Market Share in the Multicancer Screening Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Multicancer Screening Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type, End User, Region, and Competitive Landscape, Pricing Analysis, Testing Volume - Analysis and Forecast, 2023-2033

Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032

Routine Health Screening Market

DNA Diagnostics Market Size, Share and Trends Analysis Report by Technology (PCR-based Diagnostics, NGS DNA Diagnosis, in-Situ Hybridization Diagnostics), Application (Cancer Genetics Tests), and Region 2024-2030

Lung Cancer Screening Software Market Size, Share and Trends Analysis Report by Region (North America (U.S., Canada, Mexico), APAC, Europe, Latin America, MEA) 2024-2030